These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 35247438)
1. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders. Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI Life Sci; 2022 May; 296():120448. PubMed ID: 35247438 [TBL] [Abstract][Full Text] [Related]
2. The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells. Zarei Shandiz S; Assaran Darban R; Javid H; Ghahremanloo A; Hashemy SI Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):5875-5882. PubMed ID: 38334824 [TBL] [Abstract][Full Text] [Related]
3. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice. Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954 [TBL] [Abstract][Full Text] [Related]
4. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification. Rezaei S; Assaran Darban R; Javid H; Hashemy SI Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606 [TBL] [Abstract][Full Text] [Related]
5. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis. Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989 [TBL] [Abstract][Full Text] [Related]
6. The neurokinin-1 receptor in addictive processes. Schank JR J Pharmacol Exp Ther; 2014 Oct; 351(1):2-8. PubMed ID: 25038175 [TBL] [Abstract][Full Text] [Related]
7. Substance P promotes the recovery of oxidative stress-damaged retinal pigmented epithelial cells by modulating Akt/GSK-3β signaling. Baek SM; Yu SY; Son Y; Hong HS Mol Vis; 2016; 22():1015-23. PubMed ID: 27582624 [TBL] [Abstract][Full Text] [Related]
8. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Nizam E; Erin N Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097 [TBL] [Abstract][Full Text] [Related]
9. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer. Mozafari M; Ebrahimi S; Darban RA; Hashemy SI Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230 [TBL] [Abstract][Full Text] [Related]
10. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605 [TBL] [Abstract][Full Text] [Related]
11. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief. Jensen DD; Lieu T; Halls ML; Veldhuis NA; Imlach WL; Mai QN; Poole DP; Quach T; Aurelio L; Conner J; Herenbrink CK; Barlow N; Simpson JS; Scanlon MJ; Graham B; McCluskey A; Robinson PJ; Escriou V; Nassini R; Materazzi S; Geppetti P; Hicks GA; Christie MJ; Porter CJH; Canals M; Bunnett NW Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566424 [TBL] [Abstract][Full Text] [Related]
12. Substance P and the Neurokinin-1 Receptor: The New CRF. Schank JR; Heilig M Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150 [TBL] [Abstract][Full Text] [Related]
13. Substance P enhances the local activation of NK Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655 [TBL] [Abstract][Full Text] [Related]
14. Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation. Sosulina L; Strippel C; Romo-Parra H; Walter AL; Kanyshkova T; Sartori SB; Lange MD; Singewald N; Pape HC J Neurophysiol; 2015 Oct; 114(4):2500-8. PubMed ID: 26334021 [TBL] [Abstract][Full Text] [Related]
15. The neuropeptide substance P/neurokinin-1 receptor system and diabetes: From mechanism to therapy. Kokabi F; Ebrahimi S; Mirzavi F; Ghiasi Nooghabi N; Hashemi SF; Hashemy SI Biofactors; 2023; 49(3):534-559. PubMed ID: 36651605 [TBL] [Abstract][Full Text] [Related]
16. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses. Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877 [TBL] [Abstract][Full Text] [Related]
17. Neurokinin 1 Receptor Antagonists for Pruritus. Alam M; Buddenkotte J; Ahmad F; Steinhoff M Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531 [TBL] [Abstract][Full Text] [Related]
18. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645 [TBL] [Abstract][Full Text] [Related]
19. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells. Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203 [TBL] [Abstract][Full Text] [Related]
20. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Ebrahimi S; Javid H; Alaei A; Hashemy SI Clin Genet; 2020 Oct; 98(4):322-330. PubMed ID: 32266968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]